Antidepressants in Pregnancy Do Not Affect Child Neurodevelopment

TUESDAY, Oct. 4, 2022 (HealthDay News) -- Antidepressant use in pregnancy is not associated with an increased risk for neurodevelopmental disorders in children, according to a study published online Oct. 3 in JAMA Internal Medicine.
Elizabeth A. Suarez, M.P.H., Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the association between antidepressant use in pregnancy and neurodevelopmental outcomes in children using data from cohorts of publicly and privately insured pregnant individuals and their children. A total of 1.93 million pregnancies in the Medicaid Analytic eXtract and 1.25 million pregnancies in the IBM MarketScan Research Database were recorded. Children were followed from birth for a maximum of 14 years. Data were included for 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies.
The researchers found that the crude results suggested up to a doubling in the risk for neurodevelopmental outcomes in association with exposure to antidepressants; however, in fully adjusted analyses, no association was observed. Comparing antidepressant-exposed with unexposed siblings, the hazard ratios (95 percent confidence intervals) were 0.97 (0.88 to 1.06), 0.86 (0.60 to 1.23), 0.94 (0.81 to 1.08), 0.77 (0.42 to 1.39), 1.01 (0.88 to 1.16), 0.79 (0.54 to 1.17), 1.00 (0.45 to 2.22), and 0.95 (0.80 to 1.12) for any neurodevelopmental disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, specific learning disorders, developmental speech/language disorders, developmental coordination disorder, intellectual disability, and behavioral disorders, respectively.
"Antidepressant exposure during pregnancy could be an important marker for early screening and intervention in children, with the goal of improving outcomes for neurodevelopmental disorders," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Related Posts
New Malaria Treatment Gets First Approval for Use in Children
MONDAY, March 14, 2022 (HealthDay News) -- A new drug that can cure a certain...
Fully Vaccinated Woman Infected With Omicron Just 21 Days After Delta Infection
THURSDAY, April 21, 2022 (HealthDay News) -- A fully vaccinated health care...
FDA Approves First Drug Meant to Ease Alzheimer Disease-Linked Agitation
THURSDAY, May 11, 2023 (HealthDay News) -- A medication to treat agitation in...
School COVID Outbreaks Drop When Adults Wear Masks, Study Finds
WEDNESDAY, Dec. 22, 2021 (HealthDay News) -- Of course kids make up the bulk of...